Efficient Sialylation with Phenyltrifluoroacetimidates as Leaving Groups

Sialylation with N-phenyltrifluoroacetimidates as leaving groups and a catalytic amount of TMSOTf as promoter compares favorably with the previous protocols for direct sialylation and expand in essence the scope of the Schmidt glycosylation reaction

Efficient Sialylation with Phenyltrifluoroacetimidates as Leaving Groups

Sialylation with N-phenyltrifluoroacetimidates as leaving groups and a catalytic amount of TMSOTf as promoter compares favorably with the previous protocols for direct sialylation and expand in essence the scope of the Schmidt glycosylation reaction

Practical Synthesis of 3β-Amino-5-cholestene and Related 3β-Halides Involving <i>i</i>-Steroid and Retro-<i>i</i>-Steroid Rearrangements

Derivatives of 3β-amino-5-cholestene (3β-cholesterylamine) are of substantial interest as cellular probes and have potential medicinal applications. However, existing syntheses of 3β-amino-5-cholestene are of limited preparative utility. We report here a practical method for the stereoselective preparation of 3β-amino-5-cholestene, 3β-chloro-5-cholestene, 3β-bromo-5-cholestene, and 3β-iodo-5-cholestene from inexpensive cholesterol. A sequential i-steroid/retro-i-steroid rearrangement promoted by boron trifluoride etherate and trimethylsilyl azide converted cholest-5-en-3β-ol methanesulfonate to 3β-azido-cholest-5-ene with retention of configuration in 93% yield

Selective Disruption of Early/Recycling Endosomes: Release of Disulfide-Linked Cargo Mediated by a <i>N</i>-Alkyl-3β-Cholesterylamine-Capped Peptide

Selective Disruption of Early/Recycling Endosomes: Release of Disulfide-Linked Cargo Mediated by a N-Alkyl-3β-Cholesterylamine-Capped Peptid

Synthesis and Biological Evaluation of Analogues of AKT (Protein Kinase B) Inhibitor-IV

Inhibitors of the PI3-kinase/AKT (protein kinase B) pathway are under investigation as anticancer and antiviral agents. The benzimidazole derivative AKT inhibitor-IV (ChemBridge 5233705) affects this pathway and exhibits potent anticancer and antiviral activity. To probe its biological activity, we synthesized AKT inhibitor-IV and 21 analogues using a novel six-step route based on ZrCl4-catalyzed cyclization of 1,2-arylenediamines with α,β-unsaturated aldehydes. We examined effects on viability of HeLa carcinoma cells, viability of normal human cells (NHBE), replication of recombinant parainfluenza virus 5 (PIV5) in HeLa cells, and replication of the intracellular bacterium Mycobacterium fortuitum in HeLa cells. Replacement of the benzimidazole N-ethyl substitutent of AKT inhibitor-IV with N-hexyl and N-dodecyl groups enhanced antiviral activity and cytotoxicity against the cancer cell line, but these compounds showed substantially lower toxicity (from 6-fold to >20-fold) against NHBE cells and no effect on M. fortuitum, suggesting inhibition of one or more host protein(s) required for proliferation of cancer cells and PIV5. The key structural elements identified here may facilitate identification of targets of this highly biologically active scaffold